Leanne Holes

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Ajay K. Gopal, Brad S. Kahl, Sven de Vos et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia

Susan O’Brien, Nicole Lamanna, Thomas J. Kipps et al. · Blood · 2015 · 240 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +9

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, John C. Byrd, Jennifer R. Brown et al. · Blood · 2010 · 124 citations

Medicine, Oncology, Pharmacology +12

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad S. Kahl, John C. Byrd, Ian W. Flinn et al. · Blood · 2010 · 109 citations

Medicine, Oncology, Pharmacology +12

Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia.

Steven Coutré, John C. Byrd, Richard R. Furman et al. · Journal of Clinical Oncology · 2011 · 69 citations

Medicine, Oncology, Pharmacology +16